Abciximab
Antipyrine may increase the anticoagulant activities of Abciximab.
Abiraterone
The serum concentration of Antipyrine can be increased when it is combined with Abiraterone.
Acebutolol
Antipyrine may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Antipyrine is combined with Aceclofenac.
Acemetacin
The risk or severity of adverse effects can be increased when Antipyrine is combined with Acemetacin.
Acenocoumarol
Antipyrine may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetaminophen
The risk or severity of adverse effects can be increased when Antipyrine is combined with Acetaminophen.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Antipyrine.
Acetyl Sulfisoxazole
The metabolism of Antipyrine can be decreased when combined with Acetyl sulfisoxazole.
Advertisement
Aclarubicin
Antipyrine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Antipyrine.
Alclometasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.
Aliskiren
Antipyrine may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Antipyrine.
Alprenolol
Antipyrine may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Antipyrine.
Amcinonide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Amcinonide.
Amikacin
Antipyrine may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Antipyrine may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Aminosalicylic Acid.
Amiodarone
The metabolism of Antipyrine can be decreased when combined with Amiodarone.
Ancrod
Antipyrine may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Antipyrine is combined with Androstenedione.
Anhydrous Tacrolimus
Antipyrine may increase the nephrotoxic activities of Tacrolimus.
Antithrombin III
Antipyrine may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Antipyrine may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Antipyrine can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Azapropazone.
Apixaban
Antipyrine may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Antipyrine is combined with Apremilast.
Aprepitant
The serum concentration of Antipyrine can be increased when it is combined with Aprepitant.
Arbekacin
Antipyrine may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Antipyrine may increase the anticoagulant activities of Ardeparin.
Argatroban
Antipyrine may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Antipyrine may increase the anticoagulant activities of Argatroban.
Armodafinil
The metabolism of Antipyrine can be decreased when combined with Armodafinil.
Artemether
The metabolism of Antipyrine can be decreased when combined with Artemether.
Asenapine
Antipyrine may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ginseng.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Antipyrine.
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Antipyrine.
Atazanavir
The metabolism of Antipyrine can be decreased when combined with Atazanavir.
Atenolol
Antipyrine may decrease the antihypertensive activities of Atenolol.
Atomoxetine
The metabolism of Antipyrine can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Antipyrine is combined with Atorvastatin.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Antipyrine.
azficel-T
The risk or severity of adverse effects can be increased when Antipyrine is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Antipyrine.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Antipyrine.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Antipyrine.
Azithromycin
The metabolism of Antipyrine can be decreased when combined with Azithromycin.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Antipyrine.
Balsalazide
Antipyrine may increase the nephrotoxic activities of Balsalazide.
Bazedoxifene
Antipyrine may increase the thrombogenic activities of Bazedoxifene.
Becaplermin
Antipyrine may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Antipyrine.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Antipyrine.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Antipyrine.
Betamethasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Betamethasone.
Betaxolol
The metabolism of Antipyrine can be decreased when combined with Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Antipyrine.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Antipyrine.
Bisoprolol
Antipyrine may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Antipyrine may increase the anticoagulant activities of Bivalirudin.
Boceprevir
The metabolism of Antipyrine can be decreased when combined with Boceprevir.
Bopindolol
Antipyrine may decrease the antihypertensive activities of Bopindolol.
Bortezomib
The metabolism of Antipyrine can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Antipyrine can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Antipyrine can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Antipyrine.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Antipyrine.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Antipyrine.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Antipyrine.
Budesonide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Antipyrine is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Antipyrine.
Bupranolol
Antipyrine may decrease the antihypertensive activities of Bupranolol.
Bupropion
The metabolism of Antipyrine can be decreased when combined with Bupropion.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Antipyrine.
Caffeine
The metabolism of Antipyrine can be decreased when combined with Caffeine.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Antipyrine.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Antipyrine.
Capecitabine
The metabolism of Antipyrine can be decreased when combined with Capecitabine.
Capsaicin
The risk or severity of adverse effects can be increased when Antipyrine is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Captopril.
Carbamazepine
The metabolism of Antipyrine can be increased when combined with Carbamazepine.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Antipyrine.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Antipyrine.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Antipyrine.
Carteolol
Antipyrine may decrease the antihypertensive activities of Carteolol.
Carvedilol
Antipyrine may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Antipyrine.
Celiprolol
Antipyrine may decrease the antihypertensive activities of Celiprolol.
Ceritinib
The serum concentration of Antipyrine can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Antipyrine.
Certoparin
Antipyrine may increase the anticoagulant activities of Certoparin.
Chloramphenicol
The metabolism of Antipyrine can be decreased when combined with Chloramphenicol.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Antipyrine.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine.
Chlorotrianisene
Antipyrine may increase the thrombogenic activities of Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Antipyrine is combined with Chlorphenesin.
Chlorpromazine
The metabolism of Antipyrine can be decreased when combined with Chlorpromazine.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Antipyrine.
Cholecalciferol
The metabolism of Antipyrine can be decreased when combined with Cholecalciferol.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Antipyrine.
Ciclesonide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Cilazapril.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Antipyrine.
Cimetidine
The metabolism of Antipyrine can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Antipyrine can be decreased when combined with Cinacalcet.
Cinoxacin
Antipyrine may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Antipyrine may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Antipyrine is combined with Cisplatin.
Citalopram
The metabolism of Antipyrine can be decreased when combined with Citalopram.
Citric Acid
Antipyrine may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Antipyrine may increase the anticoagulant activities of Citric Acid.
Clarithromycin
The metabolism of Antipyrine can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Antipyrine can be decreased when combined with Clemastine.
Clobazam
The metabolism of Antipyrine can be decreased when combined with Clobazam.
Clobetasol
The risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Clodronic Acid.
Clofezone
The metabolism of Antipyrine can be decreased when combined with Rabeprazole.
Clomipramine
The metabolism of Antipyrine can be decreased when combined with Clomipramine.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Antipyrine.
Clopidogrel
The metabolism of Antipyrine can be decreased when combined with Clopidogrel.
Clotrimazole
The metabolism of Antipyrine can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Antipyrine can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Antipyrine can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Antipyrine can be decreased when combined with Cocaine.
Colesevelam
Colesevelam can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Antipyrine.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Cortisone acetate.
Crisaborole
The metabolism of Antipyrine can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Antipyrine can be decreased when combined with Crizotinib.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Antipyrine.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Antipyrine.
Cyclosporine
Antipyrine may increase the nephrotoxic activities of Cyclosporine.
Cyproterone Acetate
The serum concentration of Antipyrine can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
Antipyrine may increase the anticoagulant activities of Dabigatran etexilate.
Dabrafenib
The serum concentration of Antipyrine can be decreased when it is combined with Dabrafenib.
Dalteparin
Antipyrine may increase the anticoagulant activities of Dalteparin.
Danaparoid
Antipyrine may increase the anticoagulant activities of Danaparoid.
Dapsone
The risk or severity of adverse effects can be increased when Dapsone is combined with Antipyrine.
Darifenacin
The metabolism of Antipyrine can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Antipyrine can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Antipyrine can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Antipyrine can be increased when it is combined with Dasatinib.
Daunorubicin
Antipyrine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Deferasirox
The serum concentration of Antipyrine can be decreased when it is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Antipyrine is combined with Deflazacort.
Delavirdine
The metabolism of Antipyrine can be decreased when combined with Delavirdine.
Desipramine
The metabolism of Antipyrine can be decreased when combined with Desipramine.
Desirudin
Antipyrine may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Antipyrine.
Dexamethasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Antipyrine.
Dextran
Antipyrine may increase the anticoagulant activities of Dextran.
Dextran 40
Antipyrine may increase the anticoagulant activities of Dextran 40.
Dextran 70
Antipyrine may increase the anticoagulant activities of Dextran 70.
Dextran 75
Antipyrine may increase the anticoagulant activities of Dextran 75.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Antipyrine.
Dicumarol
Antipyrine may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Antipyrine may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Antipyrine may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Antipyrine.
Difluprednate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Antipyrine.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Antipyrine.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Antipyrine.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Antipyrine.
Dihydrostreptomycin
Antipyrine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Diltiazem
The metabolism of Antipyrine can be decreased when combined with Diltiazem.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Antipyrine.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Antipyrine.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Antipyrine.
Diphenhydramine
The metabolism of Antipyrine can be decreased when combined with Diphenhydramine.
Dipyrone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Metamizole.
Dothiepin
The metabolism of Antipyrine can be decreased when combined with Dosulepin.
Doxorubicin
Antipyrine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.
Doxorubicin Hydrochloride
The metabolism of Antipyrine can be decreased when combined with Doxorubicin.
Doxycycline
The metabolism of Antipyrine can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Antipyrine can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Antipyrine can be decreased when combined with Dronedarone.
Drospirenone
Antipyrine may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Antipyrine is combined with Droxicam.
Duloxetine
The metabolism of Antipyrine can be decreased when combined with Duloxetine.
Edetic Acid
Antipyrine may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Antipyrine may increase the anticoagulant activities of Edoxaban.
Efavirenz
The metabolism of Antipyrine can be decreased when combined with Efavirenz.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Icosapent.
Eliglustat
The metabolism of Antipyrine can be decreased when combined with Eliglustat.
Enalapril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Antipyrine is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Antipyrine is combined with Enalaprilat.
Enoxacin
Antipyrine may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Antipyrine may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Antipyrine may increase the anticoagulant activities of Enoxaparin.
Enzalutamide
The serum concentration of Antipyrine can be decreased when it is combined with Enzalutamide.
Epirubicin
Antipyrine may decrease the excretion rate of Epirubicin which could result in a higher serum level.
Eplerenone
Antipyrine may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Antipyrine.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Antipyrine.
Equol, (-)-
Antipyrine may increase the thrombogenic activities of Equol.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Antipyrine.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Antipyrine.
Erythromycin
The metabolism of Antipyrine can be decreased when combined with Erythromycin.
Escitalopram
Escitalopram may increase the antiplatelet activities of Antipyrine.
Eslicarbazepine Acetate
The metabolism of Antipyrine can be decreased when combined with Eslicarbazepine acetate.
Esmolol
Antipyrine may decrease the antihypertensive activities of Esmolol.
Esomeprazole
The metabolism of Antipyrine can be decreased when combined with Esomeprazole.
Estradiol
Antipyrine may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Antipyrine may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Antipyrine may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Antipyrine may increase the thrombogenic activities of Estradiol valerate.
Estriol
Antipyrine may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Antipyrine may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Antipyrine may increase the thrombogenic activities of Estrogens, esterified.
Estrone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Antipyrine.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Antipyrine.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Antipyrine.
Ethinyl Estradiol
Antipyrine may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Antipyrine may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Antipyrine is combined with Etodolac.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Antipyrine.
Etoricoxib
The risk or severity of adverse effects can be increased when Antipyrine is combined with Etoricoxib.
Etravirine
The metabolism of Antipyrine can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Antipyrine is combined with Evening primrose oil.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Antipyrine.
Felodipine
The metabolism of Antipyrine can be decreased when combined with Felodipine.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Antipyrine.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Antipyrine.
Ferulic Acid
Antipyrine may increase the anticoagulant activities of Ferulic acid.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Antipyrine.
Fish Oils
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fish oil.
Fleroxacin
Antipyrine may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Antipyrine.
Floxuridine
The metabolism of Antipyrine can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Antipyrine can be decreased when combined with Fluconazole.
Fludrocortisone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fludrocortisone.
Fluindione
Antipyrine may increase the anticoagulant activities of Fluindione.
Flumequine
Antipyrine may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Antipyrine is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluorometholone.
Fluorouracil
The metabolism of Antipyrine can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Antipyrine can be decreased when combined with Fluoxetine.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Antipyrine.
Fluticasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone propionate.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Antipyrine.
Fluvoxamine
The metabolism of Antipyrine can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Antipyrine.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Antipyrine.
Fondaparinux
Antipyrine may increase the anticoagulant activities of Fondaparinux.
Fondaparinux sodium
Antipyrine may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Antipyrine is combined with Formestane.
Fosamprenavir
The metabolism of Antipyrine can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Antipyrine can be increased when it is combined with Fosaprepitant.
Fosinopril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Fosinopril.
Fosphenytoin
The metabolism of Antipyrine can be increased when combined with Fosphenytoin.
Framycetin
Antipyrine may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Antipyrine.
Fusidate
The serum concentration of Antipyrine can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Antipyrine can be increased when it is combined with Fusidic Acid.
Gatifloxacin
Antipyrine may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Antipyrine may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Antipyrine.
Gemfibrozil
The metabolism of Antipyrine can be decreased when combined with Gemfibrozil.
Gemifloxacin
Antipyrine may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Antipyrine may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Antipyrine may increase the thrombogenic activities of Genistein.
Gentamicin
Antipyrine may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ginseng.
Grepafloxacin
Antipyrine may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Antipyrine is combined with Haloperidol.
Heparin
Antipyrine may increase the anticoagulant activities of Heparin.
Hydralazine
Antipyrine may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Antipyrine.
Hydrocortisone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Antipyrine.
Hypoxis hemerocallidea root extract
The serum concentration of Antipyrine can be decreased when it is combined with St. John's Wort.
Ibandronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Antipyrine.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Antipyrine.
Icatibant
The risk or severity of adverse effects can be increased when Antipyrine is combined with Icatibant.
Idarubicin
Antipyrine may decrease the excretion rate of Idarubicin which could result in a higher serum level.
Idelalisib
The metabolism of Antipyrine can be decreased when combined with Idelalisib.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Antipyrine.
Imatinib
The metabolism of Antipyrine can be decreased when combined with Imatinib.
Imidapril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Imidapril.
Imipramine
The metabolism of Antipyrine can be decreased when combined with Imipramine.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Antipyrine.
Indinavir
The metabolism of Antipyrine can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Antipyrine can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Antipyrine is combined with Indobufen.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.
Irbesartan
The metabolism of Antipyrine can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Antipyrine can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Antipyrine can be decreased when combined with Isavuconazonium.
Isoniazid
The metabolism of Antipyrine can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Antipyrine can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Antipyrine can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Antipyrine can be increased when it is combined with Ivacaftor.
Kanamycin
Antipyrine may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Antipyrine may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Antipyrine.
Ketoconazole
The metabolism of Antipyrine can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Antipyrine.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ginseng.
Labetalol
Antipyrine may decrease the antihypertensive activities of Labetalol.
Lapatinib
The metabolism of Antipyrine can be decreased when combined with Lapatinib.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Antipyrine.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Antipyrine.
Leflunomide
The metabolism of Antipyrine can be decreased when combined with Leflunomide.
Lepirudin
Antipyrine may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Antipyrine may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Antipyrine may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Antipyrine may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Antipyrine may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Antipyrine.
Lidocaine
The metabolism of Antipyrine can be decreased when combined with Lidocaine.
Limonene, (+)-
The risk or severity of adverse effects can be increased when Antipyrine is combined with (4R)-limonene.
Lisinopril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Antipyrine is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Antipyrine.
Lithium
The serum concentration of Lithium can be increased when it is combined with Antipyrine.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Antipyrine.
Lomefloxacin
Antipyrine may increase the neuroexcitatory activities of Lomefloxacin.
Lopinavir
The metabolism of Antipyrine can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Antipyrine can be decreased when combined with Lorcaserin.
Lornoxicam
The risk or severity of adverse effects can be increased when Antipyrine is combined with Lornoxicam.
Losartan
The metabolism of Antipyrine can be decreased when combined with Losartan.
Loteprednol
The risk or severity of adverse effects can be increased when Antipyrine is combined with Loteprednol.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Antipyrine.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Antipyrine.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Antipyrine.
Luliconazole
The serum concentration of Antipyrine can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Antipyrine can be increased when it is combined with Lumacaftor.
Lumefantrine
The metabolism of Antipyrine can be decreased when combined with Lumefantrine.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antipyrine.
Manidipine
The metabolism of Antipyrine can be decreased when combined with Manidipine.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Antipyrine.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.
Medronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Antipyrine.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Antipyrine.
Mepindolol
Antipyrine may decrease the antihypertensive activities of Mepindolol.
Mesalamine
Antipyrine may increase the nephrotoxic activities of Mesalazine.
Mestranol
Antipyrine may increase the thrombogenic activities of Mestranol.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Antipyrine.
Methadone
The metabolism of Antipyrine can be decreased when combined with Methadone.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Antipyrine.
Methotrimeprazine
The metabolism of Antipyrine can be decreased when combined with Methotrimeprazine.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Antipyrine.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Antipyrine.
Methylprednisolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Methylprednisolone.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Antipyrine.
Metipranolol
Antipyrine may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Antipyrine.
Metrizamide
Antipyrine may decrease the excretion rate of Metrizamide which could result in a higher serum level.
Mexiletine
The metabolism of Antipyrine can be decreased when combined with Mexiletine.
Midostaurin
The metabolism of Antipyrine can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Antipyrine can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the antiplatelet activities of Antipyrine.
Mirabegron
The metabolism of Antipyrine can be decreased when combined with Mirabegron.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Antipyrine.
Mitotane
The serum concentration of Antipyrine can be decreased when it is combined with Mitotane.
Moclobemide
The metabolism of Antipyrine can be decreased when combined with Moclobemide.
Modafinil
The metabolism of Antipyrine can be decreased when combined with Modafinil.
Moexipril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Antipyrine.
Moxifloxacin
Antipyrine may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antipyrine.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.
Nabilone
The metabolism of Antipyrine can be decreased when combined with Nabilone.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Antipyrine.
Nadolol
Antipyrine may decrease the antihypertensive activities of Nadolol.
Nadroparin
Antipyrine may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Antipyrine.
Nalidixic Acid
Antipyrine may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Antipyrine.
Nebivolol
Antipyrine may decrease the antihypertensive activities of Nebivolol.
Nefazodone
The metabolism of Antipyrine can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Antipyrine can be decreased when combined with Nelfinavir.
Neomycin
Antipyrine may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Antipyrine.
Netilmicin
Antipyrine may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Netupitant
The serum concentration of Antipyrine can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Antipyrine can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Antipyrine can be decreased when combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Antipyrine.
Nicotine
The metabolism of Antipyrine can be decreased when combined with Nicotine.
Nicotine Polacrilex
The metabolism of Antipyrine can be decreased when combined with Nicotine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Niflumic Acid.
Nilotinib
The metabolism of Antipyrine can be decreased when combined with Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Nimesulide.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Antipyrine.
Norfloxacin
Antipyrine may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Antipyrine is combined with Evening primrose oil.
Ofloxacin
Antipyrine may increase the neuroexcitatory activities of Ofloxacin.
Olaparib
The metabolism of Antipyrine can be decreased when combined with Olaparib.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Antipyrine.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Antipyrine.
Olsalazine
Antipyrine may increase the nephrotoxic activities of Olsalazine.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Antipyrine is combined with Omacetaxine mepesuccinate.
Omeprazole
The metabolism of Antipyrine can be decreased when combined with Omeprazole.
Osimertinib
The serum concentration of Antipyrine can be increased when it is combined with Osimertinib.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Antipyrine.
Oxprenolol
Antipyrine may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Antipyrine.
Palbociclib
The serum concentration of Antipyrine can be increased when it is combined with Palbociclib.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Antipyrine.
Pamidronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Pamidronate.
Panobinostat
The serum concentration of Antipyrine can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Antipyrine can be decreased when combined with Pantoprazole.
Paramethasone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Antipyrine is combined with Parecoxib.
Paromomycin
Antipyrine may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
The metabolism of Antipyrine can be decreased when combined with Paroxetine.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Antipyrine.
Pefloxacin
Antipyrine may increase the neuroexcitatory activities of Pefloxacin.
Peginterferon Alfa-2b
The serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Antipyrine may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Antipyrine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentobarbital
The metabolism of Antipyrine can be increased when combined with Pentobarbital.
Pentosan Polysulfate
Antipyrine may increase the anticoagulant activities of Pentosan Polysulfate.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Antipyrine.
Perindopril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Perindopril.
Phenindione
Antipyrine may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Antipyrine can be increased when combined with Phenobarbital.
Phenprocoumon
Antipyrine may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Antipyrine.
Phenytoin
The metabolism of Antipyrine can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antipyrine.
Pindolol
Antipyrine may decrease the antihypertensive activities of Pindolol.
Pioglitazone
The metabolism of Antipyrine can be decreased when combined with Pioglitazone.
Pirarubicin
Antipyrine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Antipyrine.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Antipyrine.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Antipyrine.
Plazomicin
Antipyrine may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plicamycin
Antipyrine may decrease the excretion rate of Plicamycin which could result in a higher serum level.
Polyestradiol Phosphate
Antipyrine may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Antipyrine.
Pomalidomide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Pomalidomide.
Posaconazole
The metabolism of Antipyrine can be decreased when combined with Posaconazole.
Potassium Citrate
Antipyrine may increase the anticoagulant activities of Potassium Citrate.
Practolol
Antipyrine may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Antipyrine.
Prasterone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Prasterone.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Antipyrine.
Prednicarbate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Pregnenolone.
Prilocaine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Prilocaine.
Primidone
The metabolism of Antipyrine can be increased when combined with Primidone.
Probenecid
The serum concentration of Antipyrine can be increased when it is combined with Probenecid.
Promazine
The metabolism of Antipyrine can be decreased when combined with Promazine.
Promestriene
Antipyrine may increase the thrombogenic activities of Promestriene.
Propafenone
Antipyrine may decrease the antihypertensive activities of Propafenone.
Propranolol
Antipyrine may decrease the antihypertensive activities of Propranolol.
protein C, human
Antipyrine may increase the anticoagulant activities of Protein C.
protein S, human
Antipyrine may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Antipyrine may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Antipyrine can be decreased when combined with Pyrimethamine.
Quazepam
The serum concentration of Antipyrine can be increased when it is combined with Quazepam.
Quinapril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Quinapril.
Quinestrol
Antipyrine may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Antipyrine.
Quinidine
The metabolism of Antipyrine can be decreased when combined with Quinidine.
Quinine
The metabolism of Antipyrine can be decreased when combined with Quinine.
Rabeprazole
The metabolism of Antipyrine can be decreased when combined with Rabeprazole.
Ramipril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Ramipril.
Ranolazine
The metabolism of Antipyrine can be decreased when combined with Ranolazine.
Rescinnamine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.
Reviparin
Antipyrine may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Antipyrine may increase the anticoagulant activities of Reviparin.
Rifabutin
The metabolism of Antipyrine can be increased when combined with Rifabutin.
Rifampin
The metabolism of Antipyrine can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Antipyrine can be increased when combined with Rifapentine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Antipyrine.
Rimexolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Risedronate.
Ritonavir
The metabolism of Antipyrine can be decreased when combined with Ritonavir.
Rivaroxaban
Antipyrine may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Antipyrine is combined with Rofecoxib.
Rolapitant
The metabolism of Antipyrine can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Antipyrine can be decreased when combined with Ropinirole.
Rosiglitazone
The metabolism of Antipyrine can be decreased when combined with Rosiglitazone.
Rosoxacin
Antipyrine may increase the neuroexcitatory activities of Rosoxacin.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Antipyrine.
Rucaparib
The metabolism of Antipyrine can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Antipyrine.
Salicylamide
The risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Antipyrine.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Antipyrine.
Saquinavir
The metabolism of Antipyrine can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Antipyrine can be decreased when combined with Saquinavir.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Antipyrine.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Antipyrine.
Secobarbital
The metabolism of Antipyrine can be increased when combined with Secobarbital.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Antipyrine is combined with Serrapeptase.
Sertraline
The metabolism of Antipyrine can be decreased when combined with Sertraline.
Sildenafil
The metabolism of Antipyrine can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Antipyrine can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Antipyrine can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Antipyrine.
Sisomicin
Antipyrine may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Antipyrine may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Antipyrine.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Antipyrine.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Antipyrine.
Sorafenib
The metabolism of Antipyrine can be decreased when combined with Sorafenib.
Sotalol
Antipyrine may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Antipyrine may increase the neuroexcitatory activities of Sparfloxacin.
Spectinomycin
Antipyrine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.
Spirapril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Spirapril.
Spironolactone
Antipyrine may decrease the antihypertensive activities of Spironolactone.
ST. JOHN'S WORT EXTRACT
The serum concentration of Antipyrine can be decreased when it is combined with St. John's Wort.
Streptomycin
Antipyrine may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin
Antipyrine may decrease the excretion rate of Streptozocin which could result in a higher serum level.
Sulfadiazine
The metabolism of Antipyrine can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Antipyrine can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Antipyrine.
Sulfisoxazole
The metabolism of Antipyrine can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Antipyrine.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Antipyrine.
synthetic conjugated estrogens, A
Antipyrine may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Antipyrine may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Antipyrine may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Antipyrine.
Talinolol
Antipyrine may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Antipyrine.
Tamoxifen
The metabolism of Antipyrine can be decreased when combined with Tamoxifen.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Technetium Tc-99m medronate.
Telaprevir
The metabolism of Antipyrine can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Antipyrine can be decreased when combined with Telithromycin.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Antipyrine.
Temafloxacin
Antipyrine may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Antipyrine is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Antipyrine.
Terbinafine
The metabolism of Antipyrine can be decreased when combined with Terbinafine.
Terbutaline
Antipyrine may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Antipyrine may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The serum concentration of Antipyrine can be decreased when it is combined with Teriflunomide.
Tertatolol
Antipyrine may decrease the antihypertensive activities of Tertatolol.
Theophylline
The metabolism of Antipyrine can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Antipyrine can be decreased when combined with Theophylline.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Antipyrine.
Thiotepa
The metabolism of Antipyrine can be decreased when combined with Thiotepa.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Tiaprofenic acid.
Tibolone
Antipyrine may increase the thrombogenic activities of Tibolone.
Ticagrelor
The metabolism of Antipyrine can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Antipyrine can be decreased when combined with Ticlopidine.
Tiludronate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Tiludronic acid.
Timolol
Antipyrine may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Antipyrine may decrease the antihypertensive activities of Timolol.
Tipranavir
The metabolism of Antipyrine can be decreased when combined with Tipranavir.
Tixocortol
The risk or severity of adverse effects can be increased when Antipyrine is combined with Tixocortol.
Tobramycin
Antipyrine may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocilizumab
The serum concentration of Antipyrine can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Antipyrine can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Antipyrine.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Antipyrine.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Antipyrine.
Topiramate
The metabolism of Antipyrine can be decreased when combined with Topiramate.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Antipyrine.
Trandolapril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Antipyrine.
Tranylcypromine
The metabolism of Antipyrine can be decreased when combined with Tranylcypromine.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Antipyrine.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Antipyrine.
Triamcinolone
The risk or severity of adverse effects can be increased when Antipyrine is combined with Triamcinolone.
Triamterene
Antipyrine may decrease the antihypertensive activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Antipyrine.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Antipyrine.
Trimethoprim
The metabolism of Antipyrine can be decreased when combined with Trimethoprim.
Trisodium Citrate Anhydrous
Antipyrine may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Antipyrine is combined with Trolamine salicylate.
Trovafloxacin
Antipyrine may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Antipyrine may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Antipyrine.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Antipyrine.
Valproate
The metabolism of Antipyrine can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Antipyrine can be decreased when combined with Valproic Acid.
Valrubicin
Antipyrine may decrease the excretion rate of Valrubicin which could result in a higher serum level.
Valsartan
The metabolism of Antipyrine can be decreased when combined with Valsartan.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Antipyrine.
Vemurafenib
The serum concentration of Antipyrine can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Antipyrine can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Antipyrine can be decreased when combined with Verapamil.
Voriconazole
The metabolism of Antipyrine can be decreased when combined with Voriconazole.
Warfarin
Antipyrine may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Antipyrine can be decreased when combined with Zafirlukast.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Antipyrine.
Ziprasidone
The metabolism of Antipyrine can be decreased when combined with Ziprasidone.
Zofenopril
The risk or severity of adverse effects can be increased when Antipyrine is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Antipyrine is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Antipyrine is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Antipyrine is combined with Zomepirac.
